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Apolipoprotein D (ApoD), a lipocalin transporter of small hydrophobic molecules, plays an important role in several neuro-
degenerative diseases. ApoD is expressed in and secreted from a variety of peripheral and brain tissues. Increments of ApoD have
been reported in relation with oxidative stress conditions, aging, and degeneration in the nervous system. Preliminary ﬁndings
support the role of ApoD in neuroprotection. However, its role in PD remains unclear. To date, no studies have been performed on
the relationship between ApoD in the blood and PD, as neurodegenerative pathology related to oxidative damage.We investigated
the concentration of ApoD in the blood of healthy control subjects and PD patients with mild-to-moderate neurological im-
pairment. ApoD plasma levels were measured using sandwich enzyme-linked immunosorbent assays (ELISA) in 90 healthy
subjects (aging-analysis cohort) and in 66 PD patients at diﬀerent stages compared with 19 age-matched healthy subjects.
Signiﬁcant age-related increase of ApoD was detected in subjects older than 65 years of age (p< 0.002). In PD patients,
a signiﬁcant increase in ApoD plasma concentration was found compared with healthy subjects of the same age (p< 0.05). ApoD
and PD stage are signiﬁcantly correlated (p< 0.05). ApoD might be a valid marker for the progression of PD.
1. Introduction
Aging is the most signiﬁcant risk factor for neurodegener-
ative disorders [1].*e progressive age-dependent increase in
oxidative stress and inﬂammation (“inﬂamm-aging”) rep-
resents a conserved and central mechanism of the functional
decline occurring in old humans by impairing the dynamic
organization of neuronal networks [2, 3]. It is involved in the
pathogenesis of several of the major age-related diseases
(i.e., cardiovascular disease, type 2 diabetes, and dementia)
[4, 5]. *e combined age-related induction of both proin-
ﬂammatory cytokines, tumor necrosis factor α (TNF-α), and
interleukine 6 (IL-6), in parallel with a decrease in antioxi-
dant defence has been suggested to indicate morbidity and
mortality in aged individuals [6]. *e nervous system (NS) is
the central regulator of aging [7]. Parkinson’s disease (PD) is
the second most common age-related neurodegenerative
disorder beside Alzheimer’s disease (AD) by aﬀecting 1% of
the population older than 65 years [8]. Parkinson’s disease is
a chronic progressive disease clinically manifested by bra-
dykinesia, rigidity, postural instability, and tremor. Both
idiopathic and the rare inherited PD reﬂect the pathological
increase in the oxidative stress and inﬂammation-related
events. *e progressive loss of dopaminergic neurons of
the substantia nigra (SN) and the presence of Lewy bodies
within the same area are the main distinct and neuropath-
ological hallmarks of PD [9]. *e resulting dopamine (DA)
depletion in their synaptic terminals leads to the cardinal
motor symptoms of PD through the formation of dangerous
hydroxyl radicals in the presence of ferrous ions [10–12].
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*e selective dopaminergic neuronal vulnerability is linked
to the high iron levels characterizing the SN [11]. Increased
levels of oxidized lipids, proteins, and DNA and decreased
levels of the antioxidant reduced glutathione were detected
in the SN of PD patient [13, 14]. Glutathione reduction is
linked to an increased release of the arachidonic acid (AA)
via phospholipase A2 followed by an accumulation of re-
active oxygen species/reactive nitrogen species (ROS/RNS)
and inﬂammatory mediators [15]. *us, it has been sug-
gested that limiting AA release and metabolism, a function
performed by the atypical lipocalin apolipoprotein D
(ApoD), will provide beneﬁt in the early event in the
pathogenesis of PD [16, 17].
Apolipoprotein D (ApoD) is a 29 kDa glycoprotein
member of the lipocalin family [18]. It comprises an eight-
stranded antiparallel β-barrel ﬂanked by an α-helix. *is
structure forms a calyx consisting in a hydrophobic ligand
pocket that binds AA and progesterone with higher aﬃnity
than other small ligands [18, 19]. In humans, ApoD is mainly
produced in the plasma and in the brain, in which it is highly
expressed in both the white frontal cortex and temporal
cortex, in the SN and in the cerebellum. *e lowest levels of
this lipocalin were found in the hippocampus [20, 21]. In
a healthy NS, ApoD is expressed by glia (astrocytes, oli-
goastrocytes, and Schwann cells) and other nonneuronal
cells (e.g., pericytes), and it profoundly aﬀects the function
and survival of neurons [18]. In addition to its role in ex-
tracellular lipid transport, ApoD modulates AA metabolism
in an antioxidant and anti-inﬂammatory manner [22].
ApoD stabilizes membranes-associated AA by attenuating
its release from phospholipids [17]. It traps free AA via
sequestration and prevents its consequent conversion into
oxidants or into proinﬂammatory eicosanoids. In addition,
ApoD was also demonstrated to reduce hydroperoxides of
AA (i.e., eicosatetraenoic acid) to lipid hydroxides, thereby
avoiding lipid peroxidation chain reactions and modulating
inﬂammatory pathways [23]. According to its neuro-
protective role, ApoD was found to be upregulated in brains
aﬀected by neurological (ischemic stroke), neurodegenera-
tive (AD, PD, Niemann-Pick type C disease, transmissible
spongiform encephalopathy), and psychiatric disorders
(schizophrenia and bipolar disorder). *ese diseases are
characterized by an altered brain AA metabolism and an
increased excitotoxicity. Elevated levels of ApoDmRNA and
protein were detected in brains after degeneration processes
[15]. In contrast to the NS, the expression of ApoD in body
ﬂuids was not investigated in much detail during aging.
Based on the emerging neuroprotective roles of ApoD the
aim of this pilot study was to evaluate (1) ApoD levels in
a cohort of healthy controls to verify the eﬀect of aging on
ApoD as well as the levels of TNF-α in order to get a better
insight of the increase in ApoD during the “inﬂamm-aging”
process [2, 24], (2) diﬀerences in ApoD levels between PD
and age-matched healthy controls, and (3) diﬀerences in
ApoD levels according to diﬀerent levels of neurological
impairment.
*us, our pilot study was aimed to validate if ApoD may
therefore be a reliable candidate as a marker for PD and/or
in the progression of the disease.
2. Materials and Methods
2.1. Subjects. 66 patients with PD (mean age 72.84± 7.07
years) and 19 age-matched healthy controls (mean age 72.79±
1.55 years) were enrolled.*ey were white Americans, whose
plasma was provided from the Harvard NeuroDiscovery
Center Biomarker Study (HBS).*ey underwent neurological
evaluation before enrollment. Inclusion criteria were a di-
agnosis of PD conﬁrmed according to the United Kingdom
Parkinson’s Disease Society Brain Bank criteria (bradyki-
nesia, muscular rigidity, rest tremor, and postural instability
not caused by primary visual, vestibular, cerebellar, or pro-
prioceptive dysfunction). PD patients were receiving phar-
macological therapy (monoamine oxidase-B inhibitors) for
PD because of ethical reasons.
Exclusion criteria were any other physiological/
pathological factors that can exert an inﬂuence on the
plasmatic ApoD concentration such as poststroke and/or
traumatic brain injury, antipsychotic drugs treatment,
obesity (body mass index> 27), idiopathic normal pressure
hydrocephalus, Paget’s disease, breast cancer, adenocarci-
noma of the prostate, glucose- 6-phosphate deﬁciency, and
insulin resistance-related disorders. Patients with PD were
subdivided in the following two groups based on their stage
of the disease (Hoehn and Yahr classiﬁcation): 1.0–1.5
(group A, n � 21) and ≥2.0 (group B, n � 45).
90 healthy European Caucasian subjects were enrolled
(mean age 52.05± 19.86 years) from Italy, Austria, and
Eastern Europe. *ey were recruited from among persons
who showed no sign of neurological disease and any
physiological/pathological factors that can inﬂuence ApoD
concentration. Healthy controls were subdivided in the
following age groups: 20–40 years (n � 30), 41–65 years
(n � 30), and >65 years (n � 30).
All participants provided written conﬁrmed consent
to participate in the study. *e study protocol was approved
by the local ethics committee of Gesundheitsbezirk Bozen/
Comprensorio Sanitario di Bolzano (Prot 0107531-BZ and
Prot 0002995-BZ).
2.2.Quantiﬁcation of PlasmaApoDandTNF-αLevel. Plasma
ApoD and TNF-α levels were determined by commercially
available enzyme-linked immunosorbent assay kits (USCN
Life Science Inc., USA). In brief, human plasma was col-
lected using ethylenediaminetetraacetic acid (EDTA) as an
anticoagulant. Samples were centrifuged for 15 minutes at
1000×g. Plasma was removed and diluted 1 :100 with
Phosphate Buﬀered Saline (PBS) (pH� 7.0). Samples were
tested in duplicates. 100 μl of each diluted standard, blank,
and human samples were precoated with a monoclonal
antibody speciﬁc to the related molecule (ApoD or TNF-α)
and incubated for 2 hours. Subsequently, all the samples were
incubated for 1 hour with 100 μl/well of a biotin-conjugated
polyclonal antibody preparation, washed 3 times with
a speciﬁc wash solution, and incubated for 30min with 100 μl
avidin conjugated horseradish peroxidase. Following the last
5 washes, 90 μl 3,3′,5,5′-tetramethylbenzidine (TMB) solu-
tion was added to each well. *e enzyme-substrate reaction
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was terminated by addition of 50 μl sulphuric acid solution in
each well and absorbance was measured spectrophotomet-
rically at a wavelength of 450 nm. e sandwich ELISA used
for detection of ApoD, and TNF-α had a sensitivity threshold
of about 1.03 ng/ml and 0.1 pg/ml, respectively.
2.3. Statistical Analysis. Because the data of the 90 Healthy
European Caucasian subjects were not normally distrib-
uted (Shapiro–Wilk test), nonparametric tests were used
for inferential statistics. e Kruskal–Wallis H test
(“one-way ANOVA on ranks”) was used to determine if
there were statistically signicant dierences between the
three groups of an independent variable (APOD). Post
hoc between-group comparisons were performed using
the Mann–Whitney U test. Since the data of the white
Americans (66 PD patients and 19 healthy subjects) were
normally distributed (Shapiro–Wilk test), parametric tests
were used for inferential statistics. e one-way analysis of
variance (ANOVA) was used to determine any statistically
signicant dierences between groups. Post hoc compar-
isons were performed using Tukey’s multiple comparison
test to evaluate whether there was any dierence between
groups after adjusting for multiple testing. Logistic re-
gression was used to predict the probability that PD stage
was inuenced by ApoD levels. Age, gender, and PD
medications were considered as covariates. Statistical an-
alyses were carried out using the SPSS® Statistics version
20.0. p< 0.05 was set as a signicant value for the rst level
of analysis.
Statistical analyses were carried out using the SPSS
Statistics version 20.0. p< 0.05 was set as a signicant value
for the rst level of analysis.
3. Results
3.1. Relationship between ApoD and Aging. Age-related
ApoD levels in the plasma of healthy subjects are shown
in Figure 1. e reported data were referred to subjects
subdivided in dierent age groups: 20–40 years (group I,
n  30), 41–65 years (group II, n  30), and >65 years (group
III, n  30). Increased ApoD levels were found only in older
subjects aged >65 years, independently of gender. As shown
in Figure 1, the increase in ApoD concentration was sig-
nicant in subjects of group III (mean 34.61± 9.21 ng/ml)
compared with subjects of group I (mean 28.28± 4.01 ng/ml)
(p< 0.001) and group II (mean 27.73± 7.26 ng/ml)
(p< 0.002). ApoD concentration did not signicantly in-
crease in subjects of group II (mean 27.73± 7.26 ng/ml)
compared with younger subjects of group I (mean 28.28±
4.01 ng/ml) (p> 0.5).us, age-related ApoD concentration
in human plasma increases signicantly in older subjects>65 years. Table 1 shows the gender-unrelated and age-
dependent ApoD increase in human plasma of healthy
European Caucasian subjects.
3.2. Relationship between TNF-α and Aging. As shown in
Figure 2, we found the following TNF-α concentrations:
0.188± 0.1 pg/ml in group I, 0.24± 0.05 pg/ml in group II,
and 0.61± 0.15 pg/ml in group III.us, the increase in TNF-
α concentration in human plasma was signicant between
groups I and II (p< 0.5) and between groups II and III
(p< 0.0001). In agreement with a previous study, TNF-α
levels in human plasma of European Caucasian subjects
during aging were found to be gender-unrelated in our study
(Table 1) [6].
3.3. Relationship between ApoD and Disease Severity in
Parkinson’s Disease. ApoD levels were compared among
control and PD subjects, who were in stages 1.0 to 5.0 in
the scale of Hoehn and Yahr (H&Y). Plasmatic ApoD levels
were higher in all PD patients (mean 104.15± 30.96 ng/ml)
compared with age-matched healthy subjects (mean 79.35±
26.25 ng/ml) (p< 0.005) (Figure 3). PD subjects were sub-
divided in the following groups (Hoehn and Yahr classi-
cation): 1.0–1.5 (group A, n  21) and ≥2.0 (group B, n  45).
Increased values of ApoD concentration were detected in PD
patients of group B (mean 109.10± 32.31 ng/ml) (p< 0.005)
compared with the healthy subjects. No dierence was found
between the 2 groups of patients. Stage and ApoD were
signicantly correlated (p< 0.05; Spearman’s r  0.116).
us, ApoD is predictive of the stage (linear regression
model) (Figure 4). ApoD levels in human plasma in PD were
found to be gender-unrelated in human plasma of the white
Americans group (Table 2).
4. Discussion
In the current study, we rst investigated if and how
“inamm-aging” inuences ApoD concentration in human
plasma. e plasmatic increase in ApoD concentration
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Figure 1: Age-dependent ApoD concentration in human plasma.
Horizontal lines show the average distribution of age-related ApoD
concentration in plasma in group I (mean 28.28± 4.01 ng/ml,
n  30, and 20–40 years), group II (mean 27.73± 7.26 ng/ml,
n  30, and 40–65 years), and group III (mean 34.61± 9.21 ng/ml,
n  30, and >65 years). e increase in ApoD concentration was
signicant in subjects of group III compared to subjects of group I
(p< 0.001) and group II (p< 0.002).
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found in subjects older than >65 years supports our hy-
pothesis. e detected velocity in ApoD increase between
group II and III reects the age-related overproduction of
the ROS/RNS and inammatory factors (p< 0.002). e
plasmatic levels of ApoD start to increase at the age-related
baseline upon which the entity of “inamm-aging” slowly
overwhelms the endogenous antioxidant and anti-
inammatory response. It would be hypothesized that
“inammatory tone” is observed to start rising before (in the
group II age range) and that the increase in ApoD takes place
later. is is highlighted by the signicant increase in TNF-α
concentration between the same groups (p< 0.0001). In
addition, the incidence and prevalence of AD, which double
every 5 years after an age of 65, contribute to the concept of
the age-related baseline discussed above [24, 25]. Our
ndings are in agreement with the emerging role of ApoD as
anti-stress protein in aging [15]. In a cross-species com-
parative analysis of transcription changes during brain ag-
ing, ApoD was identied as the most upregulated gene in the
aged brain [3]. Overexpression of the human APOD gene
increased survival under stress in the mouse and extended
the mean lifespan in Drosophila melanogaster [26, 27].
Table 1: Gender distribution of age-dependent ApoD and TNF-α levels in human plasma.
Group Age(years)
ApoD concentration (ng/ml) TNF-α concentration (pg/ml)
Females Males Total Females Males Total
I 20–40 27.40± 4.17(n  14) 28.75± 2.85(n  16) 28.28± 4.01(n  30) 0.17± 0.02(n  14) 0.20± 0.13(n  16) 0.188± 0.1(n  30)
II 40–65 27.85± 5.77(n  14) 27.65± 8.55(n  16) 27.73± 7.26∗(n  30) 0.25± 0.05(n  13) 0.24± 0.05(n  15) 0.24± 0.05∗(n  28)
III >65 31.37± 9.71(n  24) 34.65± 7.45(n  6) 34.61± 9.21∗(n  30) 0.65± 0.13(n  24) 0.62± 0.14(n  4) 0.61± 0.15∗(n  28)∗p< 0.05.
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Figure 2: Age-dependent TNF-α concentration in human plasma.
One-way analysis of variance (ANOVA) and Student’s t-test with
Tukey’s post hoc were used. Horizontal lines show the average
distribution of age-related ApoD concentration in human plasma
in group I (mean 0.188± 0.1 pg/ml, n  30, and 20–40 years), group
II (mean 0.24± 0.05 pg/ml, n  30, and 40–65 years), and group III
(0.61± 0.15 pg/ml, n  30, and >65 years). e increase in TNF-α
concentration in human plasma was signicant between groups I
and II (p< 0.05) and between groups II and III (p< 0.0001).
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Figure 3: Plasma ApoD levels in healthy subjects and in PD.
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Figure 4: Plasma ApoD levels correlate with disease severity in PD.
e linear regression analysis adjusted for age, gender, and PD
medications reveal an increase in the plasmatic levels of ApoD,
which is correlated with disease severity in PD (p< 0.01). Control
data were included in the regression analysis as PD stage 0.
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*e ApoD knockout (ApoD-KO) mouse model is charac-
terized by prematurely aged, hyperkinesia and memory def-
icits. *e loss of ApoD was found to aﬀect the age-dependent
transcriptome patterns of the cortex and hippocampus [28].
By contributing to the adaptability and plasticity occurring
against the age-related morphological atrophic changes,
ApoD protects the integrity of the NS by preserving or-
ganisms against the deleterious eﬀects of aging [15, 27, 28].
In conclusion, the results of our pilot study provide the ﬁrst
evidence of an age-dependent increase of ApoD concen-
tration in human blood plasma. In addition, they highlight
the potential utility of ApoD as a promising candidate as
a marker of the progressive inability to counterbalance the
oxidative stress-inﬂammation-related insults by endogenous
antioxidant defence.
Increasing evidences highlight the involvement of both
oxidative stress and inﬂammation in the deregulation of
plasma membrane lipid metabolism in PD and other neu-
rodegenerative disorders [5, 14, 29, 30]. Speciﬁcally, an
upregulation of the AA metabolic cascade was found in
brain regions with a chronic SN lesion [31]. Consequently,
a signiﬁcant increase in ApoD expression was shown in glial
cells in postmortem human brains of PD patients [32]. *us,
we investigated if and how ApoD concentration changes
in human plasma of PD patients at diﬀerent stages of
their disease. We detected a higher increase of ApoD in
PD patients compared to age-matched healthy subjects
(p< 0.005). Increased values of ApoD concentration were
found only in PD patients of the group B (p< 0.005). Stage
and ApoD were signiﬁcantly correlated (p< 0.05; Spear-
man’s r � 0.116). Our ﬁndings are in agreement with the
emerging role of ApoD in protecting cells against astro-
gliosis, whose increase contributes to the deterioration of
motor symptoms of PD. By being required to compensate
the loss of dopaminergic neurons as well as to control the
spreading of consequent damages, reactive astrocytes can
become dangerous once out of control. *us, astrogliosis is
a “double-edged sword.” A role for ApoD in maintaining the
glial response against the plethora of ROS/RNS and in-
ﬂammatory mediators under ﬁxed limits has been proposed
[15, 33, 34]. *e role of ApoD in modulating astrocyte re-
activity has been well demonstrated both in mouse primary
glial cultures and in vivo in controlling the on-oﬀ signals that
tune the glial response to injury [33]. In addition, ApoD
might be involved in removal of neurotoxic molecules re-
leased during cell dying [35]. ApoD has been also shown to
contribute to an autocrine-protecting mechanism in as-
trocytes, avoiding accumulation of peroxidated lipids and
altering the paraquat transcriptional response of genes in-
volved in ROS managing and the inﬂammatory response to
OS [30]. ApoD acts as a lipid transporter protein in neurite-
promoting responses, in active myelination and in axonal
outgrowth as well as a regeneration-promoting agent [33–
37]. In addition, ApoD exerts its neuroprotective role by
repairing the damaged lysosomal membranes. *e pH re-
covery in PQ-treated lysosomes is mediated by ApoD [38].
*us, all the emerging evidences supporting a central role of
ApoD in PD-associated astrogliosis can explain our detected
correlation of plasma ApoD levels with disease severity in
PD. Given this perspective, new strategies aimed to augment
ApoD neuroprotective properties together with therapeutic
approaches targeting CNS-resident immune cells such as
microglia and mast cells [15, 39]. All the patients enrolled in
the study were receiving pharmacological therapy for PD
because of ethical reasons. It has not been reported an in-
ﬂuence of the diﬀerent types of dopaminergic agents on the
expression of ApoD, whereas an increase in AA and a de-
crease in docosahexaenoic acid (DHA) concentrations were
found in postmortem brain in PD patients and parkinsonian
monkeys treated with levodopa [40]. Consequently, a pos-
sible inﬂuence of levodopa on the detected ApoD levels
cannot be excluded. In addition, a potential reduction
in ApoD levels exerted from the antioxidant eﬀects of
monoamine oxidase (MAO) inhibitors has to be considered.
*ese drugs reduced hyperactivity of MAO, which leads to
an excessive production of hydrogen peroxide involved in
neurotoxicity [41]. Interestingly, the combination of MAO
inhibitors and levodopa was found to improve cognition,
including probabilistic learning, working memory, and
executive functions [42]. *e potential contribution of
ApoD as a lipid carrier in these drugs-related remodelling
processes within the glial-neuronal networks has to be in-
vestigated. *is is the ﬁrst study of plasma ApoD in relation
to PD and its progression. *e strengths of the present study
are the large patient sample for a preliminary study and the
evaluation of eﬀects within the brain by detecting changes in
blood, a less intrusive procedure to collect from human
subjects. Its limitation is the possibility that diﬀerences
between TNF-α and ApoD concentration might also be
the reﬂection of diﬀerent tissue sources producing TNF-α
(i.e., age). In conclusion, we found a signiﬁcant increase in
the plasmatic levels of ApoD in PD, which are correlated
with disease severity (p< 0.05; Spearman’s r � 0.001). Our
study supports the idea that measuring the concentration of
ApoD in human plasma may be used as a reliable marker for
the progression of PD.
Table 2: Gender distribution of ApoD levels in human plasma in PD.
Group H&Y Age (years)
ApoD (ng/ml)
Females Males Total
A <2 71.57± 5.24 90.18± 25.70 (n � 15) 104.31± 17.90 (n � 6) 93.54± 24.47 (n � 21)
B ≥2 73.44± 8.99 107.67± 39.83 (n � 21) 111.81± 26.59 (n � 24) 109.10± 32.31 (n � 45)
All PD 1–5 72.84± 7.07 99.90± 34.63 (n � 38) 110.47± 25.25 (n � 28) 104.15± 30.96 (n � 66)
Healthy control group 72.79± 1.55 85.33± 24.32 (n � 11) 90.26± 14.29 (n � 8) 79.35± 26.25 (n � 19)∗p< 0.05.
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5. Conclusion
*is study suggests a consistent age-related physiological
increase of ApoD concentration in human plasma, especially
in subjects over an age of 65 years. Although there is
a general age-related increase in ApoD concentration during
aging, we found that plasma levels of PD patients are sig-
niﬁcantly higher than age-matched healthy subjects. Par-
kinson’s disease stage and ApoD are signiﬁcantly correlated.
*e increase in the plasmatic levels of ApoD in PD is sig-
niﬁcant even in the presence of comorbidities, potentially
compromising the lipid homeostasis as, for example, in
hyperlipidemia. Considering the sample limitations and
exploratory nature of this pilot study, further studies with
larger sample size of healthy subjects and PD patients are
recommended in order to verify the validity of ApoD that
may therefore be a reliable candidate as a marker for disease
progression.
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